This webinar will explore how insights gained through NGS translate to the development of improved treatment of lymphoid malignancies.
Registration is now open for the Invivoscribe Leukaemia and Lymphoma Molecular Diagnostics Seminar.
Abacus dx is pleased to announce the launch of the new LymphoTrack B-cell Low Positive Controls and LymphoQuant B-cell Internal Controls as part of Invivoscribe’s MRD B-Cell Bundled Solution.
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
Planning on attending EHA 2018 in Sweden?
Invivoscribe invites to you attend a dinner social. Hear about ‘Minimal Residual Disease in Multiple Myeloma by NGS: A Comparison with Flow Cytometry’.
Minimal Residual Disease (MRD) testing by Next Generation Sequencing (NGS) has become an important methodology demonstrating clear potential to optimize therapeutic management of lymphoproliferative diseases.
Visit Invivoscribe at Booth #324 at the American Society of Haematology (ASH) Meeting for information regarding NGS assays and their application for clonality testing, somatic hypermutation testing, and Minimal Residual Disease (MRD).